Eficacia analgésica de la morfina intratecal como complemento en la anestesia raquídea para cirugía cesárea
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Cuad. - Hosp. Clín.
Abstract
Introducción: El control del dolor post-cesárea, es importante para proveer a la puérpera de movilización precoz, para una recuperación rápida, de los más estudiados es la morfina, el cual muestra un perfil seguro de acción, dependiente de la dosis. Objetivo: Determinar la eficacia analgésica de la morfina intratecal como complemento en la anestesia raquídea para cirugía cesárea, en Hospital "Dr. Jorge Eduardo Olmos Maeda" San Borja - Beni de julio a septiembre del 2020. Metodología: Se realizó un ensayo clínico aleatorizado a ciegas con el propósito de evaluar la eficacia analgésica y seguridad de la administración de morfina intratecal (MIT) en la analgesia posoperatoria tras las intervenciones cesárea en el Hospital "Dr. Jorge Eduardo Olmos Maeda" San Borja - Beni en el periodo de julio - septiembre del 2020 Universo: conformado por las pacientes programadas para cesárea, se analizaron también variables como peso, edad, frecuencia de eventos adversos atribuibles al uso de opioides. Resultados: La presencia de dolor fue más frecuente en el grupo (A) que recibió dosis de 1 µgr/ kg de morfina intratecal (8/45); que en el grupo (B) que recibió dosis de 2 µgr/kg de morfina intratecal (0/45), en contraparte el grupo A, presento menores efectos adversos a opioides (3/45), que el grupo B (10/45). Conclusiones: El uso de morfina intratecal, es seguro, de acuerdo a los resultados obtenidos, pero es más recomendable el uso de 1 µgr/kg, por su buen control analgésico y frecuencia disminuida de reacciones adversas.
Introduction: Post-cesarean pain control is important to facilitate early mobilization and rapid recovery for postpartum women. Objective: To determine the analgesic efficacy of intrathecal morphine as a complement to spinal anesthesia for cesarean surgery at the Jorge Maeda Hospital in San Borja (Beni) from July to September 2020. Methodology: We conducted a double-blind randomized clinical trial to evaluate the analgesic efficacy and safety of intrathecal morphine (ITM) for postoperative pain management following cesarean interventions at the Jorge Maeda Hospital in San Borja (Beni) during the period from July to September 2020. The study population consisted of patients scheduled for cesarean section. Results: Pain was more frequent in Group A, which received a dose of 1 µg/kg intrathecal morphine (8/45), compared to Group B, which received a dose of 2 µg/kg intrathecal morphine (0/45). However, Group A had fewer adverse effects related to opioids (3/45) compared to Group B (10/45). Conclusions: The use of intrathecal morphine is safe. Based on the results obtained, a dose of 1 µg/kg is more recommendable due to its effective pain control and reduced frequency of adverse reactions.
Introduction: Post-cesarean pain control is important to facilitate early mobilization and rapid recovery for postpartum women. Objective: To determine the analgesic efficacy of intrathecal morphine as a complement to spinal anesthesia for cesarean surgery at the Jorge Maeda Hospital in San Borja (Beni) from July to September 2020. Methodology: We conducted a double-blind randomized clinical trial to evaluate the analgesic efficacy and safety of intrathecal morphine (ITM) for postoperative pain management following cesarean interventions at the Jorge Maeda Hospital in San Borja (Beni) during the period from July to September 2020. The study population consisted of patients scheduled for cesarean section. Results: Pain was more frequent in Group A, which received a dose of 1 µg/kg intrathecal morphine (8/45), compared to Group B, which received a dose of 2 µg/kg intrathecal morphine (0/45). However, Group A had fewer adverse effects related to opioids (3/45) compared to Group B (10/45). Conclusions: The use of intrathecal morphine is safe. Based on the results obtained, a dose of 1 µg/kg is more recommendable due to its effective pain control and reduced frequency of adverse reactions.
Description
Vol. 65, No. 2